Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches

Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Computers in biology and medicine 2024-11, Vol.182, p.109136, Article 109136
Hauptverfasser: Akash, Shopnil, Shanto, S.K. Hasibul Islam, Islam, Md. Rezaul, Bayil, Imren, Afolabi, Samson Olusegun, Guendouzi, Abdelkrim, Abdellattif, Magda H., Zaki, Magdi E.A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 109136
container_title Computers in biology and medicine
container_volume 182
creator Akash, Shopnil
Shanto, S.K. Hasibul Islam
Islam, Md. Rezaul
Bayil, Imren
Afolabi, Samson Olusegun
Guendouzi, Abdelkrim
Abdellattif, Magda H.
Zaki, Magdi E.A.
description Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety. Graphical illustration of the studies. [Display omitted] •This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.
doi_str_mv 10.1016/j.compbiomed.2024.109136
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3107157969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482524012216</els_id><sourcerecordid>3107157969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</originalsourceid><addsrcrecordid>eNqFkUtPAyEUhYnR2Fr9C4bEjZupPAdYan3GGje6NIRSpqWZDhVmTPz3MmkbEzeygXA_7rmcAwDEaIwRLq9WYxvWm5kPazcfE0RYvlaYlgdgiKVQBeKUHYIhQhgVTBI-ACcprRBCDFF0DAZUESXzGoKPW59s-HLxG4YKNvlUw5fpM4O-WfqZb0NM0CyMb1ILbahDdLY1NbSmsS7CdhlDt1jCfpquNa0PTS6azSYGY5cunYKjytTJne32EXi_v3ubPBbT14enyfW0sFgRWQil-NxgrpDlWHJSMVaVFDNTypmprDWUm4pLXCklKGVCKCyRNERIQRW3hI7A5bZvFv7sXGr1On_L1bVpXOiSphgJzIUqVUYv_qCr0MU8dk8RnhUk6xvKLWVjSCm6Sm-iX5v4rTHSfQR6pX8j0H0EehtBfnq-E-hmfW3_cO95Bm62gMuOfHkXdbLeZT_nvndXz4P_X-UHnQCbww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125997842</pqid></control><display><type>article</type><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</creator><creatorcontrib>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</creatorcontrib><description>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety. Graphical illustration of the studies. [Display omitted] •This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</description><identifier>ISSN: 0010-4825</identifier><identifier>ISSN: 1879-0534</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2024.109136</identifier><identifier>PMID: 39298888</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>5-Fluorouracil ; Affinity ; Anticancer properties ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Benzophenanthridines - chemistry ; Benzophenanthridines - pharmacology ; Bioavailability ; Cancer therapies ; Chemical properties ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - metabolism ; Drug development ; Drug Discovery ; Effectiveness ; Humans ; Immunotherapy ; In vivo methods and tests ; Inflammatory bowel disease ; Isoquinolines - chemistry ; Isoquinolines - pharmacology ; Isoquinolines - therapeutic use ; Kinases ; Ligands ; MAP kinase ; Medical prognosis ; Mixed lineage kinases ; Molecular docking ; Molecular Docking Simulation ; Molecular dynamics ; Molecular Dynamics Simulation ; Optimization ; Patients ; Pharmacokinetics ; Protein kinase C ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Proteins ; Sanguinarine ; Sanguinarine derivatives ; Side effects ; Simulation</subject><ispartof>Computers in biology and medicine, 2024-11, Vol.182, p.109136, Article 109136</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</cites><orcidid>0000-0003-1751-705X ; 0000-0001-8613-6539 ; 0000-0002-6174-5044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0010482524012216$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39298888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akash, Shopnil</creatorcontrib><creatorcontrib>Shanto, S.K. Hasibul Islam</creatorcontrib><creatorcontrib>Islam, Md. Rezaul</creatorcontrib><creatorcontrib>Bayil, Imren</creatorcontrib><creatorcontrib>Afolabi, Samson Olusegun</creatorcontrib><creatorcontrib>Guendouzi, Abdelkrim</creatorcontrib><creatorcontrib>Abdellattif, Magda H.</creatorcontrib><creatorcontrib>Zaki, Magdi E.A.</creatorcontrib><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><title>Computers in biology and medicine</title><addtitle>Comput Biol Med</addtitle><description>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety. Graphical illustration of the studies. [Display omitted] •This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</description><subject>5-Fluorouracil</subject><subject>Affinity</subject><subject>Anticancer properties</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Benzophenanthridines - chemistry</subject><subject>Benzophenanthridines - pharmacology</subject><subject>Bioavailability</subject><subject>Cancer therapies</subject><subject>Chemical properties</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Effectiveness</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>In vivo methods and tests</subject><subject>Inflammatory bowel disease</subject><subject>Isoquinolines - chemistry</subject><subject>Isoquinolines - pharmacology</subject><subject>Isoquinolines - therapeutic use</subject><subject>Kinases</subject><subject>Ligands</subject><subject>MAP kinase</subject><subject>Medical prognosis</subject><subject>Mixed lineage kinases</subject><subject>Molecular docking</subject><subject>Molecular Docking Simulation</subject><subject>Molecular dynamics</subject><subject>Molecular Dynamics Simulation</subject><subject>Optimization</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Protein kinase C</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proteins</subject><subject>Sanguinarine</subject><subject>Sanguinarine derivatives</subject><subject>Side effects</subject><subject>Simulation</subject><issn>0010-4825</issn><issn>1879-0534</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtPAyEUhYnR2Fr9C4bEjZupPAdYan3GGje6NIRSpqWZDhVmTPz3MmkbEzeygXA_7rmcAwDEaIwRLq9WYxvWm5kPazcfE0RYvlaYlgdgiKVQBeKUHYIhQhgVTBI-ACcprRBCDFF0DAZUESXzGoKPW59s-HLxG4YKNvlUw5fpM4O-WfqZb0NM0CyMb1ILbahDdLY1NbSmsS7CdhlDt1jCfpquNa0PTS6azSYGY5cunYKjytTJne32EXi_v3ubPBbT14enyfW0sFgRWQil-NxgrpDlWHJSMVaVFDNTypmprDWUm4pLXCklKGVCKCyRNERIQRW3hI7A5bZvFv7sXGr1On_L1bVpXOiSphgJzIUqVUYv_qCr0MU8dk8RnhUk6xvKLWVjSCm6Sm-iX5v4rTHSfQR6pX8j0H0EehtBfnq-E-hmfW3_cO95Bm62gMuOfHkXdbLeZT_nvndXz4P_X-UHnQCbww</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Akash, Shopnil</creator><creator>Shanto, S.K. Hasibul Islam</creator><creator>Islam, Md. Rezaul</creator><creator>Bayil, Imren</creator><creator>Afolabi, Samson Olusegun</creator><creator>Guendouzi, Abdelkrim</creator><creator>Abdellattif, Magda H.</creator><creator>Zaki, Magdi E.A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>JQ2</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1751-705X</orcidid><orcidid>https://orcid.org/0000-0001-8613-6539</orcidid><orcidid>https://orcid.org/0000-0002-6174-5044</orcidid></search><sort><creationdate>202411</creationdate><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><author>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>5-Fluorouracil</topic><topic>Affinity</topic><topic>Anticancer properties</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Benzophenanthridines - chemistry</topic><topic>Benzophenanthridines - pharmacology</topic><topic>Bioavailability</topic><topic>Cancer therapies</topic><topic>Chemical properties</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Effectiveness</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>In vivo methods and tests</topic><topic>Inflammatory bowel disease</topic><topic>Isoquinolines - chemistry</topic><topic>Isoquinolines - pharmacology</topic><topic>Isoquinolines - therapeutic use</topic><topic>Kinases</topic><topic>Ligands</topic><topic>MAP kinase</topic><topic>Medical prognosis</topic><topic>Mixed lineage kinases</topic><topic>Molecular docking</topic><topic>Molecular Docking Simulation</topic><topic>Molecular dynamics</topic><topic>Molecular Dynamics Simulation</topic><topic>Optimization</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Protein kinase C</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proteins</topic><topic>Sanguinarine</topic><topic>Sanguinarine derivatives</topic><topic>Side effects</topic><topic>Simulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akash, Shopnil</creatorcontrib><creatorcontrib>Shanto, S.K. Hasibul Islam</creatorcontrib><creatorcontrib>Islam, Md. Rezaul</creatorcontrib><creatorcontrib>Bayil, Imren</creatorcontrib><creatorcontrib>Afolabi, Samson Olusegun</creatorcontrib><creatorcontrib>Guendouzi, Abdelkrim</creatorcontrib><creatorcontrib>Abdellattif, Magda H.</creatorcontrib><creatorcontrib>Zaki, Magdi E.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akash, Shopnil</au><au>Shanto, S.K. Hasibul Islam</au><au>Islam, Md. Rezaul</au><au>Bayil, Imren</au><au>Afolabi, Samson Olusegun</au><au>Guendouzi, Abdelkrim</au><au>Abdellattif, Magda H.</au><au>Zaki, Magdi E.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</atitle><jtitle>Computers in biology and medicine</jtitle><addtitle>Comput Biol Med</addtitle><date>2024-11</date><risdate>2024</risdate><volume>182</volume><spage>109136</spage><pages>109136-</pages><artnum>109136</artnum><issn>0010-4825</issn><issn>1879-0534</issn><eissn>1879-0534</eissn><abstract>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety. Graphical illustration of the studies. [Display omitted] •This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>39298888</pmid><doi>10.1016/j.compbiomed.2024.109136</doi><orcidid>https://orcid.org/0000-0003-1751-705X</orcidid><orcidid>https://orcid.org/0000-0001-8613-6539</orcidid><orcidid>https://orcid.org/0000-0002-6174-5044</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0010-4825
ispartof Computers in biology and medicine, 2024-11, Vol.182, p.109136, Article 109136
issn 0010-4825
1879-0534
1879-0534
language eng
recordid cdi_proquest_miscellaneous_3107157969
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects 5-Fluorouracil
Affinity
Anticancer properties
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Benzophenanthridines - chemistry
Benzophenanthridines - pharmacology
Bioavailability
Cancer therapies
Chemical properties
Chemotherapy
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Drug development
Drug Discovery
Effectiveness
Humans
Immunotherapy
In vivo methods and tests
Inflammatory bowel disease
Isoquinolines - chemistry
Isoquinolines - pharmacology
Isoquinolines - therapeutic use
Kinases
Ligands
MAP kinase
Medical prognosis
Mixed lineage kinases
Molecular docking
Molecular Docking Simulation
Molecular dynamics
Molecular Dynamics Simulation
Optimization
Patients
Pharmacokinetics
Protein kinase C
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Proteins
Sanguinarine
Sanguinarine derivatives
Side effects
Simulation
title Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A23%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20novel%20MLK4%20inhibitors%20against%20colorectal%20cancer%20through%20computational%20approaches&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Akash,%20Shopnil&rft.date=2024-11&rft.volume=182&rft.spage=109136&rft.pages=109136-&rft.artnum=109136&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2024.109136&rft_dat=%3Cproquest_cross%3E3107157969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3125997842&rft_id=info:pmid/39298888&rft_els_id=S0010482524012216&rfr_iscdi=true